Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunodeficiency and cancer].

M C Favrot1, T Philip, C Coze

  • 1Unité fonctionelle de greffe médullaire, centre Léon-Bérard, Lyon, France.

Pediatrie
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Getting to grips with resilience: Toward large-scale phenotyping of this complex trait.

JDS communications·2024
Same author

Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.

Hepatology international·2021
Same author

Analysis of diagnosis announcements in Abidjan pediatric oncology unit 2 years after introduction of the African Pediatric Cancer Announcement Guideline.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2019
Same author

Correction to: In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.

BMC medicine·2018
Same author

Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.

Paediatric drugs·2018
Same author

Combined therapy in children and adolescents with classical Hodgkin's lymphoma: A report from the SFCE on MDH-03 national guidelines.

Pediatric hematology and oncology·2016
Same journal

[Colonic atresia: report of a case].

Pediatrie·1993
Same journal

[Psychological aspects of bone marrow donation in donor brothers and sisters in bone marrow transplantation].

Pediatrie·1993
Same journal

[Lethargy in the course of treatment with ranitidine in a newborn infant].

Pediatrie·1993
Same journal

[Delayed detection of hip dislocation: is the physician to blame?].

Pediatrie·1993
Same journal

[Renal tubular acidosis in children].

Pediatrie·1993
Same journal

[CD23: structures, functions and practical perspectives in allergy reactions].

Pediatrie·1993
See all related articles

Immunodeficiencies increase cancer risk by enabling viral infections and immune system dysregulation. These conditions can lead to hematopoietic cancers and other malignancies through various mechanisms.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Context:

  • Cancers are frequently observed in individuals with congenital, iatrogenic, or acquired immunodeficiencies.
  • Understanding the interplay between immune deficiencies and cancer development is crucial for risk assessment and therapeutic strategies.

Purpose:

  • To elucidate the role of immunodeficiencies in the pathogenesis of various cancers, particularly hematopoietic malignancies.
  • To explore the mechanisms by which immune system alterations contribute to carcinogenesis.

Summary:

  • Immunodeficiency elevates the risk of viral infections, such as Epstein-Barr virus, which can directly cause polyclonal proliferations in severe cases.
  • In moderate deficiencies, chronic immune stimulation from infections may increase mutagenic events, potentially leading to malignant clone immortalization, with or without viral involvement.

Related Experiment Videos

  • Intrinsic lymphoid cell abnormalities can underlie both immunodeficiency and carcinogenesis, as exemplified by chromosomal fragility.

    • Impact:

    • This analysis provides insights into the complex relationship between immune system status and cancer development.
    • Findings can inform the development of targeted preventative measures and therapies for high-risk populations.